In terms of BA, intrahepatic cholestasis controls and normal controls, ‘intermediate’ CD14++CD16+ Mo accounted for 4.81%, 4.67% and 1.63%, respectively; and sMac accounted for 6.72%, 5.53% and 0.06%, respectively (Figure 12; p < .0001; Appendix S11), and pDC accounted for 1.43%, 4.94% and 3.55%, respectively (Figure 12; p < .0001; Appendix S11). This evidence concerns the gene CD14 and breast angiosarcoma.